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Introduction: Recombinant factor IX Fc fusion protein (rFIXFc) is a recombinant coagulation factor composed of a
single molecule of recombinant factor IX (rFIX) covalently fused to the Fc domain of human immunoglobulin G1
(IgG1) with no intervening sequence. An extensive nonclinical program was performed to support the clinical
development of rFIXFc for treatment of people with hemophilia B.
Materials and Methods: Repeat-dose toxicology studies of rFIXFc were performed in 2 relevant species: Sprague
Dawley rats (4-week study) and cynomolgus monkeys (5- and 27-week studies). Assessments included in-life
observations, electrocardiograms (monkeys only), laboratory evaluations (including hematology and blood
chemistry), postmortem analyses, local tolerance, and pharmacokinetics (PK). Allometric scalingwas performed
with PK data from multiple species, including humans. Local tolerance (single-dose study) and thrombogenic
potential (Wessler stasis model) of rFIXFc were tested in New Zealand White rabbits.
Results: Therewere no signiﬁcant local or systemic toxicity ﬁndings in the repeat-dose studies. Allometric scaling
data suggested that animal rFIXFc PK results are predictive of humanPK parameters. Therewere noﬁndings from
the local tolerance study in rabbits; thrombogenic activity was less than that elicited by rFIX and a prothrombin
complex concentrate, and similar to vehicle control.
Conclusions: rFIXFc was well tolerated in toxicology studies and demonstrated a low thrombogenic potential.
These results are consistent with phase 1/2a and phase 3 clinical studies of rFIXFc in people with hemophilia B.© 2015 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
Hemophilia B is an X-linked hereditary bleeding disorder resulting
from factor IX (FIX) clotting factor deﬁciency. FIX prophylaxis is
considered the optimal therapy for people with hemophilia B because
it is associated with improved clinical outcomes compared withime;AUClast, areaunder the time
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. This is an open access article underepisodic treatment [1–3]. Conventional FIX products necessitate infu-
sions 2 to 3 times weekly to achieve protective factor levels. The infu-
sion frequency required for prophylaxis is likely related to the half-life
of the FIX product; thus, products with longer half-lives would require
less frequent infusions.
The ﬁrst longer-acting recombinant factor IX (rFIX) product that is
commercially available, recombinant factor IX Fc fusion protein
(rFIXFc), is composed of a single molecule of rFIX covalently fused to
the Fc domain of human immunoglobulinG1 (IgG1)withno intervening
sequence [4]. The Fc portion of rFIXFc binds to the neonatal Fc receptor
(FcRn), which is part of an endogenous pathway that delays lysosomal
degradation of Fc-containing proteins by cycling them back into circula-
tion and thus extending their plasma half-life [5,6]. An extensive non-
clinical program was performed in multiple animal species to support
clinical development of rFIXFc [7]. Additionally, a phase 1/2a study
and the phase 3 B-LONG study have demonstrated the efﬁcacy and safe-
ty of rFIXFc for the prevention and treatment of bleeding episodes in
previously treated subjects with severe hemophilia B [8,9].
Pharmacokinetic (PK) studies in mice, rats, dogs, and monkeys have
shown the prolonged half-life of rFIXFc relative to rFIX, while pharma-
codynamic studies in mice and dogs demonstrated both immediate
onset of action, as well as the prolonged clotting activity of rFIXFcthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
372 J.A. Dumont et al. / Thrombosis Research 136 (2015) 371–378relative to rFIX [7]. In this report, we describe the evaluation of the sys-
temic and local toxicological effects of rFIXFc in 2 pharmacologically rel-
evant species, rats and monkeys; the local tolerance and thrombogenic
safety in rabbits; and the degree to which rFIXFc PK parameters in ani-
mals predict those in humans.
Materials and Methods
Treatment Regimens
Study Drug
rFIXFc was produced using a stably transfected human embryonic
kidney (HEK) 293H host cell line [10]. Dosing frequencies in the
repeat-dose toxicology studies (every 4 days in rats andweekly inmon-
keys) were chosen based on elimination half-lives of approximately
1.5 days in rats and 2 to 3 days in monkeys to ensure that animals
were exposed to rFIXFc on a continuous basis.
Repeat-dose Study in Rats
The systemic and local toxicological effects of rFIXFc were evaluated
in Sprague Dawley rats in a 4-week, repeat-dose study in compliance
with Good Laboratory Practice (GLP) standards. A total of 100 rats
were included in the core toxicology group, and an additional 120 rats
were included in a satellite group for PK and immunogenicity studies
(Table 1). Rats received intravenous (IV) administration of rFIXFc
every 4 days for 4 weeks and were euthanized 1 day after the last
dose (terminal necropsy on Day 30). A cohort of rats in the high-dose
and control groups were euthanized after a 4-week recovery period,
followed by recovery necropsy (Day 57) to assess potential reversal of
toxicological effects.
Repeat-dose Studies in Monkeys
rFIXFc was evaluated for local tolerance and systemic toxicological
effects in cynomolgus monkeys in a 5-week, repeat-dose study in com-
pliance with GLP standards. A total of 32monkeys were included in the
study (Table 1). Monkeys received IV administration of rFIXFc once
weekly for 5 weeks, followed by a 4-week recovery period for a cohort
of monkeys in the high-dose and control groups. Animals were
euthanized for terminal necropsy 1 day after the last dose (Day 31) or
recovery necropsy 4 weeks later (Day 58).
Local and systemic toxicological effects of rFIXFc in cynomolgus
monkeys were also evaluated in a 27-week, repeat-dose study, also inTable 1
Experimental Designs of Repeat-dose Toxicology Studies of rFIXFc.
Study rFIXFc dose
(IU/kg)
Number of
M, F
Terminal
necropsya
Recovery
necropsyb
4-week rat studyc 0 15 M, 15 F 10 M, 10 F 5 M, 5 F
50 10 M, 10 F 10 M, 10 F None
200 10 M, 10 F 10 M, 10 F None
1000 15 M, 15 F 10 M, 10 F 5 M, 5 F
5-week monkey studyd 0 5 M, 5 F 3 M, 3 F 2 M, 2 F
50 3 M, 3 F 3 M, 3 F None
200 3 M, 3 F 3 M, 3 F None
1000 5 M, 5 F 3 M, 3 F 2 M, 2 F
27-week monkey studye 0 6 M, 6 F 4 M, 4 F 2 M, 2 F
50 4 M, 4 F 4 M, 4 F None
200 4 M, 4 F 4 M, 4 F None
1000 6 M, 6 F 4 M, 4 F 2 M, 2 F
rFIXFc, recombinant factor IX Fc fusion protein; M, male; F, female; PK, pharmacokinetic.
a Day 30 in the 4-week rat study, Day 31 in the 5-week monkey study, and Day 184 in
the 27-week monkey study.
b Day 57 in the 4-week rat study, Day 58 in the 5-week monkey study, and Day 212 in
the 27-week monkey study.
c Animals received rFIXFc on Days 1, 5, 9, 13, 17, 21, 25, and 29. A satellite group of rats
(an additional 15 M and 15 F per dose group) were used for PK and immunogenicity
evaluations.
d Animals received rFIXFc on Days 1, 8, 15, 22, and 30.
e Animals received rFIXFc weekly for 27 weeks.compliance with GLP standards. A total of 40 monkeys were included in
this study (Table 1).Monkeys receivedweekly IV administration of rFIXFc
for 27 weeks, followed by a 4-week recovery period for a cohort of mon-
keys in the high-dose and control groups. Monkeys were euthanized for
terminal necropsy on Day 184, and recovery necropsy on Day 212.
Single-dose Local Tolerance Study in Rabbits
A local tolerance study evaluated injection site reactions for both the
liquid and lyophilized formulations of rFIXFc using 20 male New
Zealand White rabbits. Each rabbit was given 4 infusions: single IV
(intended clinical route of administration) and paravenous infusions
on both the right ear (control) and the left ear (rFIXFc). For 10 rabbits,
liquid rFIXFc was administered using a dose of 110 IU/kg in 1 ear and
the saline control in the other ear. For the remaining 10 rabbits, lyoph-
ilized rFIXFcwas administered using a dose of 198 IU/kg in 1 ear and the
vehicle control in the other ear. For each treatment group, 5 rabbits
were euthanized onDay4, and5 rabbitswere euthanized onDay14. Re-
sults were similar for both formulations of rFIXFc, and only results using
the lyophilized formulation are reported here.
Toxicology
Toxicology parameters evaluated in the repeat-dose studies includ-
ed in-life observations (eg, clinical observations, body weight, food
consumption, ophthalmic examination), laboratory evaluations (eg, he-
matology, serum chemistry, coagulation parameters [prothrombin time
(PT), activated partial thromboplastin time (aPTT), and FIX activity by
modiﬁed 1-stage clotting assay (27-week monkey study only)]), post-
mortem analyses (eg, gross necropsy, organ weights, histopathology),
and local tolerance evaluations (eg, gross and microscopic examination
of IV injection sites). In addition, cardiovascular assessments were
performed for all monkeys. In the 5-weekmonkey study, electrocardio-
grams (ECGs) were recorded pretest, 1 hour postdose on Days 22 and
27, and during theweek prior to the scheduled Day 58 necropsy for an-
imals in the recovery cohort. In the 27-week monkey study, ECGs were
recorded pretest, 1 hour postdose on Days 64 and 120, during theweek
prior to the scheduled core cohort necropsy, and during the week prior
to the recovery necropsy for monkeys in the recovery cohort. Heart rate
was determined manually from the ECG recordings.
Immunogenicity (formation of anti-rFIXFc antibodies) was analyzed
in a satellite group of rats (n=30 per dose group) and in all monkeys in
both studies via blood samples collected predose on Days 1, 17, 29, and
57 (rat study); Days 1, 15, 30, and 58 (5-week monkey study); or Days
1, 29, 92, 183, and 212 (27-week monkey study). After processing, each
plasma sample was assessed for the presence of anti-rFIXFc antibodies
by Prevalere Life Sciences, Inc. (Whitesboro, NY, USA) using a validated
enzyme-linked immunosorbent assay (ELISA) [7]. For samples that test-
ed positive, an immunocompetition assaywas performed to conﬁrm an-
tibody response. Speciﬁcity of the antibodies against the Fc and FIX
domains of the rFIXFc molecule was also determined during the
immunocompetition assay. Speciﬁcity was assigned based on a change
in signal upon the addition of Fc, FIX, or rFIXFc to the sample compared
with the addition of saline; a change in signal of ≥25% indicated speciﬁc-
ity.When antibody speciﬁcity to the Fc and/or FIXmoieties could not be
ascertained, speciﬁcity was assigned to the whole rFIXFc molecule.
Pharmacokinetics
PK evaluations were performed for the repeat-dose studies. In the
4-week rat study, blood samples were collected on Days 1 and 29
(predose and 0.25, 1, 8, 24, 48, 72, 96, 120, and 144 hours postdose)
for determination of plasma rFIXFc concentration. In the 27-weekmon-
key study, blood samples were obtained for the ﬁrst dose on Day 1
(predose and 0.25, 1, 8, 24, 48, 72, 96, 120, and 168 hours postdose);
on Days 29 and 92 (predose and 0.25, 1, 8, and 24 hours postdose);
and on Day 183 (predose and 0.25, 1, 8, and 24 hours postdose for all
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373J.A. Dumont et al. / Thrombosis Research 136 (2015) 371–378terminal and recovery necropsies; and 48, 72, 96, 120, and 168 hours
postdose for recovery necropsies). PK results from the 5-week monkey
studywere similar to those from the 27-week study, and are reported in
Table S1 and Figure S1.
Analysis of rFIXFc plasma concentration was performed using a val-
idated ELISA [7] by Prevalere Life Sciences, Inc. PK analysis was based on
individual animal concentration-time point data and dosage informa-
tion and was performed by Battelle (Columbus, OH, USA). Plasma
concentration-time data were analyzed by noncompartmental analysis
using WinNonlin® software version 5.0.1 (Pharsight Corporation,
Mountain View, CA, USA). The PK parameters determined and evaluat-
ed included maximum plasma concentration (Cmax), area under the
time versus plasma concentration curve from the time of dose adminis-
tration to the last measurable concentration (AUClast), elimination half-
life (t1/2), volume of distribution at steady state (Vss), clearance, and
mean residence time (MRT). Mean ± standard deviation (SD) plasma
concentration-time curves for each group were constructed. PK param-
eters were summarized by group. No statistical analysis comparisons
within a group or across groups were made, other than those that
could be performed using simple descriptive statistical analysis.
Allometric Scaling
Plasma clearance and Vss were modeled using allometric scaling
(log-log plot) to determine their relationship to body weight across 4
animal species (mice, rats, dogs, andmonkeys) and subjectswith hemo-
philia B. PK data were previously obtained (mouse data from 15 sepa-
rate PK proﬁles [4-6 mice per time point]; rat data from 8 separate
proﬁles [5-6 rats per time point]; dog data from 2 individual proﬁles;
monkey data from 66 individual proﬁles; and human data from a
phase 1/2a study [n = 12] and the phase 3 B-LONG clinical study
[n = 117], which were plotted separately in this analysis [unpublished
data and other studies [7–9,11]]).
Local Tolerance Study in Rabbits
Injection sites on rabbits were evaluated by limited gross examina-
tion and histopathology on Days 4 and 14 after dosing.
Thrombogenicity Evaluation
Early, crude replacement FIX preparations often contained small
amounts of activated FIX (FIXa), which can cause thrombosis [12]. The
potential thrombogenic activity of rFIXFc after IV administration to New
Zealand White rabbits was assessed using an unmodiﬁed Wessler stasis
model [13]. Forty-two male rabbits were assigned to 1 of 7 dose groups,
with 6 rabbits per group. Each animal was infused with a bolus injection
of saline, dilution vehicle, rFIXFc (50, 200, or 1000 IU/kg), plasma-derived
prothrombin complex concentrate (Proﬁlnine® SD; 198 IU/kg), or rFIX
(BeneFIX®; 991 IU/kg). The number and type of thrombi were assessed
and scored (blinded reviewer) using a semiquantitative scale of 0 to 4
(0, no clots; 1, a few macroscopic strands of ﬁbrin; 2, several small
thrombi; 3, ≥2 large thrombi; and 4, single thrombus forming a cast of
the isolated vein segment).
Statistical Analyses
For the 27-week, repeat-dose monkey study, all appropriate in-life
and postmortem data collected were analyzed statistically (when n
≥3). Data were analyzed for effects of rFIXFc by analysis of variance. Ho-
mogeneity was assessed using Bartlett’s test at the 0.05 level. For data
for which variances were considered homogenous across test groups,
tests for differences between the control group and comparison groups
were made using Dunnett’s test. For nonhomogenous data, tests for
pair-wise differences between the control group and each of the
comparison groups were made using Cochran and Cox’s modiﬁed
374 J.A. Dumont et al. / Thrombosis Research 136 (2015) 371–3782-sample t test. Statistical signiﬁcance for each comparison was report-
ed at the 0.05 level.
Results
Repeat-dose Toxicology Studies in Rats and Monkeys
Toxicology
rFIXFc was well tolerated in the repeat-dose toxicology studies in
rats andmonkeys. There were no adverse toxicological ﬁndings directly
related to effects of rFIXFc, as assessed by multiple in-life parameters
(Table 2). These parameters included cardiovascular evaluation ofmon-
keys in both the 5-week and 27-week studies, which showed ECGs and
heart rates within normal limits for the control and rFIXFc dosing
groups. There were also no local tolerance ﬁndings related to rFIXFc.
The single abnormal clinical observation attributed to rFIXFc adminis-
tration was a mild hypersensitivity reaction in 2 male monkeys in the
high-dose group during the 27-week study. The reactions consisted pri-
marily of splotchy reddening of the face, ears, nose, and/or scrotal areas.
In 1 monkey, the reaction was observed intermittently beginning at
Week 5 and ending at Week 9; the other monkey presented reactions
sporadically beginning atWeek 9 and ending atWeek 18. Each instance
of the reaction was typically noted within a few hours postdose and
resolved within 4 days postdose.
Laboratory evaluations of rats andmonkeys also showed no adverse
effects attributed to rFIXFc treatment (Table 2). During the 27-week
study in monkeys, globulin levels for vehicle control–treated animals
varied between 2.7 g/dL and 2.9 g/dL in males, and between 2.7 g/dL
and 3.2 g/dL in females. There was no impact of rFIXFc treatment on
globulin levels; all values from treated animals were comparable to
the vehicle control ranges formales and females. A lack of effect on glob-
ulin levels was also seen in the 4-week study in rats and in the 5-week
study inmonkeys. Furthermore,modiﬁed aPTT and aPTT analyses in the
27-week monkey study (performed prior to dosing on Days 1, 29, 92,Table 3
Incidence of Antibodies to rFIXFc in the Repeat-dose Studies.a
4-week rat study
Study day
Dose (IU/kg) 1 17
0 0/24 0/24
50 0/24 1/24
200 1/24 5/24
1000 0/24 10/24
5-week monkey study
Study day
Dose (IU/kg) 1 15
0 0/10 0/10
50 0/6 0/6
200 0/6 0/6
1000 0/10 1/10
27-week monkey study
Study day
Dose (IU/kg) 1 29 92
0 0/12 0/12 1/12
50 0/8 1/8 3/8
200 0/8 2/8 4/8
1000 0/12 9/12 11/1
rFIXFc, recombinant factor IX Fc fusion protein; NA, not applicable.
a Data shown are the number of animals with anti-rFIXFc antibodies/total number of anima
b One antibody-positive monkey also tested positive for the presence of antibodies on Day 3and 183, and on Day 212 of the recovery period) conﬁrmed that there
were no effects on endogenous FIX activity. Postmortem evaluations
also showed no direct toxicological effects of rFIXFc in the repeat-dose
studies (Table 2).
Immunogenicity assessments showed that repeated administration
of rFIXFc resulted in a number of rats and monkeys testing positive for
the presence of anti-rFIXFc antibodies (Table 3). This observation was
expected because rFIXFc is a fully human, and thus foreign, protein in
both rats and monkeys. For all repeat-dose studies, antibody formation
was dose- and time-dependent. In the 4-week rat study, 40 of 72 rFIXFc-
treated animals tested positive for antibodies during the study. The ma-
jority of these antibody-positive rats (n=37) had antibodies speciﬁc to
the Fc portion of the drug, while antibodies from 1 rat were speciﬁc to
both the Fc and FIX regions; the antibody speciﬁcity to Fc or FIX could
not be determined for 2 rats based on the deﬁned signal threshold in
the immunocompetition assay, and thus speciﬁcity was assigned to
the whole rFIXFc molecule. The percentage of dosed animals with
detectable antibody response to rFIXFc increased slightly as dose in-
creased. Of note, 6 animals in the vehicle control group and 1 animal
in the mid-dose group (on Day 1 prior to the ﬁrst dose, and at other
time points) tested positive for anti-rFIXFc antibodies; however, the
signals measured in these animals were just above the assay cut-point
and are unlikely to indicate an antibody response to rFIXFc.
In the 5-weekmonkey study, 12 of 22 animals dosedwith rFIXFc test-
ed positive for antibody formation. For those monkeys that tested posi-
tive at the end of the study (Day 30; n = 9), 3 had antibodies speciﬁc
to the Fc portion of the drug, 3 had antibodies speciﬁc to the FIX domain,
and 3 had antibodies of undetermined speciﬁcity. Overall, the speciﬁcity
of antibodies that developed in the 5-week monkey study was roughly
divided between the FIX and Fc domains; in contrast, the majority of an-
tibodies showed speciﬁcity for the Fc domain in the 4-week rat study.
In the 27-week monkey study, 18 of 28 monkeys dosed with rFIXFc
tested positive for anti-rFIXFc antibodies. In addition, 1 monkey in the
control group tested positive on Days 92 and 183. Antibodies were29 57
(recovery group)
Overall
4/24 4/24 6/24
3/24 9/24 10/24
10/24 13/24 13/24
16/24 16/24 17/24
30 58
(recovery group)
Overall
0/10 0/4 0/10
1/6 NA 1/6
2/6 NA 2/6
6/10 4/4b 9/10
183 212
(recovery group)
Overall
1/12 0/4 1/12
3/8 NA 3/8
4/8 NA 4/8
2 11/12 3/4 11/12
ls per group (equal number male and female).
0, while the remaining 3 monkeys had not previously tested positive.
Table 4
Key PK Parameters for rFIXFc in the 4-week, Repeat-dose Study in Rats.a
Cmax (μg/mL) AUClast (h·μg/mL) t1/2 (h) Vss (mL/kg) CL (mL/h/kg)
Dose group Day 1 Day 29 Day 1 Day 29 Day 1 Day 29 Day 1 Day 29 Day 1 Day 29
50 IU/kg 6.7 6.0 118 102 26.7 27.1 183 245 7.66 9.35
200 IU/kg 25.7 18.4 383 265 28.8 23.5 233 366 9.56 14.9
1000 IU/kg 163 138 1240 813 34.5 16.8 288 283 13.88 24.8
PK, pharmacokinetic; rFIXFc, recombinant factor IX Fc fusion protein; Cmax, maximumplasma concentration; AUClast, area under the time versus plasma concentration curve from the time
of dose administration to the last measurable concentration; t1/2, elimination half-life; Vss, volume of distribution at steady state; CL, clearance.
a For each dosing group, n = 24 (males and females).
Table 5
Key PK Parameters for rFIXFc in the 27-week, Repeat-dose Study in Monkeys.a
Cmax (μg/mL) AUClast(h·μg/mL) t1/2 (h) Vss (mL/kg) CL (mL/h/kg)
Dose group n Day 1 Day 29 Day 1 Day 29 Day 1 Day 29 Day 1 Day 29 Day 1 Day 29
50 IU/kg 8 7.1 ± 1.1 8.5b ± 0.7 168 ± 22.8 92.6b ± 13.3 47.1 ± 6.9 NRc 232 ± 45.5 NRc 5.03 ± 0.66 NRc
200 IU/kg 8 42.3 ± 7.8 40.3 ± 4.4 848 ± 145 410 ± 129 58.0 ± 13.1 NRd 180 ± 26.4 NRd 3.99 ± 0.73 NRd
1000 IU/kg 12 240 ± 48.0 240 ± 36.2 3486 ± 451 1396 ± 434 48.5 ± 11.8 4.1e ± 2.3 187 ± 43.3 51.2e ± 18.7 4.94 ± 0.80 14.0e ± 5.3
PK, pharmacokinetic; rFIXFc, recombinant factor IX Fc fusion protein; Cmax, maximumplasma concentration; AUClast, area under the time versus plasma concentration curve from the time
of dose administration to the last measurable concentration; t1/2, elimination half-life; Vss, volume of distribution at steady state; CL, clearance; NR, not reported.
a Data are reported as mean ± standard deviation.
b n = 7.
c Only calculated for 1 of 7 animals (data for remaining animals not suitable for analysis).
d Only calculated for 2 of 8 animals (data for remaining animals not suitable for analysis).
e n = 11.
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but no further increase was observed on Day 183. The majority of anti-
bodies were speciﬁc to the FIX domain (n = 13, including 1 monkey
from the control group),while antibodies from 2monkeyswere speciﬁcDay 29Day 1
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Fig. 1. rFIXFc plasma concentration during the 27-week, repeat-dose monkey study. (A) Plasm
(B) AUClast versus study day for high-dose group (rFIXFc 1000 IU/kg; n = 12).a rFIXFc, recomb
curve from the time of dose administration to the last measurable concentration. aData represeto the Fc domain, and 4 monkeys had antibodies speciﬁc to both the Fc
and FIX domains. As demonstrated in the following PK analyses, the
presence of antibodies in rats and monkeys led to more rapid elimina-
tion of rFIXFc in some animals later in the studies.Day 183Day 92
ime (h)
100 120 140 160 180
IU/kg (n = 8) 1000 IU/kg (n = 12)
a concentration versus time curves (semi-log plot) for each dosing group on Day 1,a and
inant factor IX Fc fusion protein; AUClast, area under the time versus plasma concentration
nt mean ± standard deviation.
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adverse-effect level (NOAEL) of 1000 IU/kg, the highest dose tested, in
rats and monkeys.Pharmacokinetics
After the ﬁrst dose in rats, Cmax values were generally dose-
proportional across dose groups (Table 4). Systemic rFIXFc exposure,
as indicated by AUC values, was approximately proportional with dose
for the 50 and 200 IU/kg doses, with a somewhat less than proportional
increase at the 1000 IU/kg dose level. Clearance values ranged from 7.66
to 13.88 mL/h/kg, and group mean t1/2 values ranged from 26.7 to
34.5 hours for male and female rats at all dose levels. Repeated admin-
istration of rFIXFc was associatedwith decreases in AUC on Day 29, par-
ticularly with the mid and high doses, and concomitant increases in
clearance (with clearance values ranging from 9.35-24.8 mL/h/kg;
Table 4); these changes correlated with the appearance of anti-rFIXFc
antibodies upon repeated dosing. Consistent with the higher incidence
of antibody-positive rats at the higher dose levels, mean t1/2 values
were slightly reduced for the 1000 and 200 IU/kg dose levels compared
with the 50 IU/kg dose (16.8, 23.5, and 27.1 hours, respectively).
After the ﬁrst dose on Day 1 in the 27-week monkey study, rFIXFc
exposure increased in a dose-proportional manner, as measured by
Cmax and AUC (Table 5 and Fig. 1A); exposure was similar for males
and females within each dose group, and combined data are shown.
PK parameters, including t1/2, Vss, and clearance, were generally similar
across groups. Clearance ranged from 4.0 to 5.0 mL/h/kg, and the group
mean t1/2 ranged from 47 to 58 hours. PK parameters were assessed
again on Day 29 (Table 5); compared with Day 1, Cmax was unchanged
across all dose groups. However, Day 29 group mean values for t1/2,
AUClast, MRT, and Vss had decreased for the high-dose group compared
with Day 1, and mean clearance increased. PK parameters on Day 29
correlated with the presence of anti-rFIXFc antibodies. On Days 92 andCl
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Fig. 2. Allometric scaling analysis of rFIXFc. (A) rFIXFc clearance versus body weight in anima
recombinant factor IX Fc fusion protein; CL, clearance; Vss, volume of distribution at steady sta183, mean PK parameters were similar to values on Day 29 across all
dose groups, indicating no further effect on clearance; AUClast for the
high-dose group also remained relatively constant after Day 29
(Fig. 1B). PK parameters were similar in the 5- and 27-week, repeat-
dosemonkey studies; results for Day 1 of the 5-week study are reported
in Table S1 and Figure S1.Allometric Scaling
The allometric scaling log-log plot and equation for plasma clearance
and Vss are shown in Figs. 2A and 2B, respectively. Based on the expo-
nent from the allometric scaling plot for clearance (0.84), rFIXFc was
eliminated more rapidly in small animals (mice, rats, dogs, and mon-
keys) compared with humans. In contrast, Vss was proportional to
body weight across species (with an exponent of 0.98). The exponents
for clearance and Vss are consistent with the range of exponents for
other small molecules or other biotherapeutic proteins, which typically
range from 0.6 to 0.8 for clearance (including an exponent of 0.73 for
rFIX [14]), and from 0.8 to 1.1 for Vss [14,15].Single-dose Study in Rabbits (Local Tolerance)
There were no local tolerance ﬁndings attributed to administration
of rFIXFc in rabbits. Microscopic ﬁndings of dermal inﬂammation and
edemawere similar in incidence and severity among all treated sites, in-
cluding vehicle and control sites.Thrombogenic Safety
Using theWessler stasismodel [13], themean thrombogenic activity
of rFIXFc administered at doses of 50, 200, and 1000 IU/kgwas similar toy weight (kg)
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derived prothrombin complex concentrate and rFIX (Fig. 3).
Discussion
rFIXFc has been evaluated for its toxicological effects in 2 species,
Sprague Dawley rats and cynomolgus monkeys, and for local tolerance
and thrombogenic potential in New Zealand White rabbits. The
repeat-dose studies in rats and monkeys were of durations up to 4
and 27 weeks, respectively. Because rFIXFc binds to FcRn in both rats
andmonkeys, they were pharmacologically relevant species. Moreover,
the activities of the clotting factors in the coagulation cascade are well
conserved between these species and humans, and the IV route of ad-
ministration for the toxicology studiesmatched the route of administra-
tion used in clinical studies of rFIXFc [8,9].
rFIXFc was well tolerated in the repeat-dose toxicology studies and
did not cause any local tolerance reactions. In 2 high-dose males in the
27-weekmonkey study, a pattern consistent with a mild hypersensitiv-
ity reaction related to the development of anti-rFIXFc antibodies was
observed; both of these monkeys had developed anti-rFIXFc antibodies
by Day 29. These reactions were transient and resolved before the end
of the study. In both rats andmonkeys, the incidence of antibody devel-
opment increased with increasing dose and time, and antibodies were
“clearing” antibodies, resulting in more rapid elimination of rFIXFc
later in the study compared with Day 1. Following the development of
these antibodies, mean AUC remained dose-dependent in both rats
and monkeys, although the absolute values were lower compared
with Day 1 values. In the 27-week monkey study, there was no indica-
tion that these antibodies cross-reacted with endogenous FIX, based
on a modiﬁed aPTT analysis (data not shown). Furthermore, the lack
of histopathological changes in rats and monkeys that were treated
with rFIXFc showed that there was no evidence of organ toxicity due
to antibody/antigen complex formation. The development of antibodies
to rFIXFc was an expected ﬁnding in rats and monkeys because this
molecule is a foreign protein in both species; despite these antibodies,
the toxicology of rFIXFc was adequately assessed in the repeat-dose
studies, as exposure was maintained throughout the dosing period in
both rats and monkeys.
Importantly, administration of rFIXFc did not impact globulin levels
in the repeat-dose rat and monkey studies. Globulin levels consist pri-
marily of IgG and, as a fragment of IgG1, the Fc portion of rFIXFc binds
to the same cellular receptor as IgG [6,16]. Despite rFIXFc doses of up
to 1000 IU/kg, globulin levels were similar in the animals treated with
rFIXFc and those treated with the vehicle control in the 3 repeat-dose
studies. Thus, the results in rats and monkeys showed that administra-
tion of rFIXFc did not interferewith IgGhomeostasis. This lack of effect is
expected because the endogenous serum concentration of IgG isconsiderably higher than that of the pharmacological levels of rFIXFc.
In children and adults, the concentration of IgG in serum ranges from
520 mg/dL to 1630 mg/dL [17]. Based on the average speciﬁc activity
for rFIXFc of 70 IU/mg [10] and results of the phase 3 study of rFIXFc
in which the incremental recovery was 0.92 IU/dL per IU/kg dose
(which translates to a Cmax of 92 IU/dL for a 100 IU/kg dose) [9], the
maximum serum concentration of rFIXFc is 1.3 mg/dL. Thus, the
serum concentration of rFIXFc in a therapeutic dose range (eg, 50-100
IU/kg) is much lower than the serum concentration of endogenous IgG.
Based on empirically derived allometric scaling equations, the PK pa-
rameters of rFIXFc follow well-established guidelines for many
biotherapeutic proteins: smaller animal species (based on bodyweight)
eliminate proteinsmore rapidly than humans, and Vss is proportional to
body weight across species. While the exponent for rFIXFc clearance
(0.84) does not identify a mechanism of plasma elimination, it is never-
theless likely that the derived allometric scaling equation is due to a
similarity in clearance mechanisms across species, which includes the
role of FcRn in prolonging the elimination half-life of rFIXFc, as well as
other clearance mechanisms speciﬁc to FIX itself.
The low thrombogenic potential of rFIXFc observed in rabbits and
the normal proﬁle of PT and hematology values following repeated
rFIXFc doses of up to 1000 IU/kg in both rats and monkeys are in con-
trast to the high thrombogenic potential reported for someother, earlier
FIX products in people with hemophilia B [12]. The small, variable
amounts of FIXa contained in FIX products can lead to thrombosis, and
most highly puriﬁed FIX concentrates have shown much lower
thrombogenic potential than earlier, cruder preparations of FIX prod-
ucts. Consistent with the low thrombogenic potential observed in this
study using a Wessler stasis model, the level of FIXa has been reported
to be approximately 10 to 20 times lower in rFIXFc preparations
(b0.013%) compared with conventional rFIX (0.11% ± 0.0019%) and
plasma-derived FIX (0.21% ± 0.010%) products [7].Conclusions
Thehighest dose used in the toxicology studies, 1000 IU/kg, provides
a sufﬁcient safety margin for use of rFIXFc as a replacement coagulation
factor. The results of these toxicology studies support the clinical safety
proﬁle of rFIXFc for use in people with hemophilia B.Conﬂict of Interest Statement
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